Skip to content

Jonathan C. Javitt

3 papers in the library · publishing 2022-2023

Papers

Sort Most recent Most cited

D-cycloserine is not susceptible to self-administration using an intravenous self-administration model in male ketamine-habituated Sprague-Dawley rats.

Pharmacology, Biochemistry, and Behavior June 2023 Michael T Sapko, Taleen Hanania, Qing Chang et al.

N-methyl-d-aspartate receptor (NMDAR) antagonist antidepressants have known potential for abuse liability. The aim of this study was to evaluate the abuse liability of D-cycloserine (DCS), using a self-administration paradigm in which DCS was tested for its efficacy in substituting for ketamine in ketamine-dependent rats. A standard intravenous self-administration study was conducted in male...

NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial

International Journal of Bipolar Disorders August 13, 2022 A. Nierenberg, P. Lavin, Daniel C Javitt et al.

Background We tested the hypothesis that, after initial improvement with intravenous ketamine in patients with bipolar disorder (BD) with severe depression and acute suicidal thinking or behavior, a fixed-dose combination of oral D-cycloserine (DCS) and lurasidone (NRX-101) can maintain improvement more effectively than lurasidone alone. Methods This was a multi-center, double-blind, twostage,...

D-cycloserine (DCS) is Not Susceptible to Self-administration, unlike S-ketamine Using an Intravenous Self-administration Model in Naive and Ketamine-habituated Sprague-Dawley Rats

bioRxiv Preprint Server August 12, 2022 Daniel C Javitt, Jonathan C. Javitt preprint

OBJECTIVE N-methyl D-aspartate Receptor (NMDAR) antagonist antidepressants have known potential for abuse liability. The aim of this study was to evaluate the abuse liability of D-cycloserine (DCS), using a self-administration paradigm in which DCS was tested in its efficacy in substituting for ketamine in ketamine-dependent rats.

DOI: 10.1101/2022.08.12.503713 (opens in new tab) Full text (opens in new tab) D-cycloserine Dcs Low abuse potential Non-addictive +13